Measurable residual disease in AML

VJHemOnc has 1608 videos Subscribe Here

Description: Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the use of measurable residual disease (MRD) in acute myeloid leukemia (AML). Prof. Burnett highlights its utility as an independent predictor of outcome and questions how much MRD could displace other risk scores, as well as it's possible indication of chemosensitivity.
Shared By : VJHemOnc
Posted on : 08/21/18
Added : 1 year ago